GSK plc (GSK.L) Friday said that the China National Medical Products Administration has approved Nucala for the treatment of adults with chronic rhinosinusitis with nasal polyps (CRSwNP).
The approval is based on results from the phase 3 MERIT study, which evaluated mepolizumab versus placebo in a population of Japanese, Chinese and Russian patients with inadequately controlled CRSwNP, and is supported by data from the global phase 3 SYNAPSE study, which explored the effect of mepolizumab versus placebo in more than 400 patients with CRSwNP.
Mepolizumab is already approved in China as an add-on maintenance treatment for individuals aged 12 years and older with severe eosinophilic asthma as well as for adults with eosinophilic granulomatosis with polyangiitis.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.